A 2010 Evidence-based Algorithm for the Pharmacotherapy of Social Anxiety Disorder

Overview

Journal Curr Psychiatry Rep

Publisher Current Science

Specialty Psychiatry

Date 2010 Aug 6

PMID 20686872

Citations 10

Authors

Dan J Stein

David S Baldwin

Borwin Bandelow

Carlos Blanco

Leonardo F Fontenelle

Sing Lee

Hisato Matsunaga

David Osser

Murray B Stein

Michael Van Ameringen

Affiliations

Soon will be listed here.

Abstract

A growing evidence base on the management of social anxiety disorder has yielded many meta-analyses and guidelines on the pharmacotherapy of this clinically important condition. We aimed to update a pharmacotherapy algorithm for the treatment of social anxiety disorder that was developed to be concise and user friendly and that was addressed to the primary care practitioner in particular. The updated algorithm attempts to summarize succinctly the recent literature in this area, as well as to include the views of an international panel of experts with diverse experience. The algorithm comprises eight sequential steps, beginning with those focused on diagnosis and initiating treatment and ending with the management of the treatment-refractory patient.

Citing Articles

Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review.

Brandt J, Bressi J, Le M, Neal D, Cadogan C, Witt-Doerring J EClinicalMedicine. 2024; 70:102507.

PMID: 38516102 PMC: 10955669. DOI: 10.1016/j.eclinm.2024.102507.

Efficacy and tolerability of paroxetine in adults with social anxiety disorder: A meta-analysis of randomized controlled trials.

Li X, Hou Y, Su Y, Liu H, Zhang B, Fang S Medicine (Baltimore). 2020; 99(14):e19573.

PMID: 32243377 PMC: 7220791. DOI: 10.1097/MD.0000000000019573.

Aligning the many definitions of treatment resistance in anxiety disorders: A systematic review.

Bokma W, Wetzer G, Gehrels J, Penninx B, Batelaan N, van Balkom A Depress Anxiety. 2019; 36(9):801-812.

PMID: 31231925 PMC: 6771798. DOI: 10.1002/da.22895.

Concomitant treatment with sertraline and social skills training improves social skills acquisition in social anxiety disorder: A double-blind, randomized controlled trial.

Bernik M, Corregiari F, Savoia M, de Barros Neto T, Pinheiro C, Neto F PLoS One. 2018; 13(10):e0205809.

PMID: 30372482 PMC: 6205595. DOI: 10.1371/journal.pone.0205809.

Korean Guidelines for the Pharmacological Treatment of Social Anxiety Disorder: Initial Treatment Strategies.

Yoon H, Oh D, Suh H, Lee K, Lim S, Lee J Psychiatry Investig. 2018; 15(2):147-155.

PMID: 29475215 PMC: 5900408. DOI: 10.30773/pi.2017.05.01.

References

Blanco C, Heimberg R, Schneier F, Fresco D, Chen H, Turk C . A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry. 2010; 67(3):286-95. PMC: 2856667. DOI: 10.1001/archgenpsychiatry.2010.11. View

Versiani M, Amrein R, Montgomery S . Social phobia: long-term treatment outcome and prediction of response--a moclobemide study. Int Clin Psychopharmacol. 1998; 12(5):239-54. View

Singh J, Hope D . Cognitive-behavioral approaches to the treatment of social anxiety disorder. Isr J Psychiatry Relat Sci. 2009; 46(1):62-9. View

Kobak K, Greist J, Jefferson J, Katzelnick D . Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol. 2002; 22(3):257-62. DOI: 10.1097/00004714-200206000-00005. View

Stein D, Stein M, Goodwin W, Kumar R, Hunter B . The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and in less generalized social anxiety disorder. Psychopharmacology (Berl). 2001; 158(3):267-72. DOI: 10.1007/s002130100880. View

Stein D, Cameron A, Amrein R, Montgomery S . Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Int Clin Psychopharmacol. 2002; 17(4):161-70. DOI: 10.1097/00004850-200207000-00002. View

Fehm L, Pelissolo A, Furmark T, Wittchen H . Size and burden of social phobia in Europe. Eur Neuropsychopharmacol. 2005; 15(4):453-62. DOI: 10.1016/j.euroneuro.2005.04.002. View

Tuccori M, Testi A, Antonioli L, Fornai M, Montagnani S, Ghisu N . Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. Clin Ther. 2009; 31 Pt 1:1426-53. DOI: 10.1016/j.clinthera.2009.07.009. View

Nutt D, Montgomery S . Moclobemide in the treatment of social phobia. Int Clin Psychopharmacol. 1996; 11 Suppl 3:77-82. DOI: 10.1097/00004850-199606003-00013. View

10.

Pande A, Davidson J, Jefferson J, Janney C, Katzelnick D, Weisler R . Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol. 1999; 19(4):341-8. DOI: 10.1097/00004714-199908000-00010. View

11.

Simon N, Hoge E, Fischmann D, Worthington J, Christian K, Kinrys G . An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006; 67(3):381-5. DOI: 10.4088/jcp.v67n0307. View

12.

Baldwin D, Anderson I, Nutt D, Bandelow B, Bond A, Davidson J . Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005; 19(6):567-96. DOI: 10.1177/0269881105059253. View

13.

van Vliet I, den Boer J, Westenberg H, Pian K . Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry. 1997; 58(4):164-8. DOI: 10.4088/jcp.v58n0405. View

14.

Stein D, Ipser J, Balkom A . Pharmacotherapy for social phobia. Cochrane Database Syst Rev. 2004; (4):CD001206. DOI: 10.1002/14651858.CD001206.pub2. View

15.

Vaishnavi S, Alamy S, Zhang W, Connor K, Davidson J . Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(7):1464-9. DOI: 10.1016/j.pnpbp.2007.06.027. View

16.

Connor K, Davidson J, Churchill L, Sherwood A, Foa E, Weisler R . Psychometric properties of the Social Phobia Inventory (SPIN). New self-rating scale. Br J Psychiatry. 2000; 176:379-86. DOI: 10.1192/bjp.176.4.379. View

17.

Hitchcock C, Chavira D, Stein M . Recent findings in social phobia among children and adolescents. Isr J Psychiatry Relat Sci. 2009; 46(1):34-44. PMC: 2925835. View

18.

Davidson J, Foa E, Huppert J, Keefe F, Franklin M, Compton J . Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry. 2004; 61(10):1005-13. DOI: 10.1001/archpsyc.61.10.1005. View

19.

Pande A, Feltner D, Jefferson J, Davidson J, Pollack M, Stein M . Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004; 24(2):141-9. DOI: 10.1097/01.jcp.0000117423.05703.e7. View

20.

Aarre T . Phenelzine efficacy in refractory social anxiety disorder: a case series. Nord J Psychiatry. 2003; 57(4):313-5. DOI: 10.1080/08039480310002110. View